Chiron Mum as 2001 Passes Without Blood Test Approval
It may qualify as the least surprising biotech news of the new year, but Chiron (CHIR) failed to get its NAT blood-testing system approved by U.S. drug regulators by Dec. 31.
The Emeryville, Calif.-based biopharmaceutical firm had told investors and Wall Street analysts to expect Food and Drug Administration approval of the NAT blood test by the end of 2001. TheStreet.com cast significant doubt on that prediction in late November, when a top U.S. blood-banking official said the heft of the approval application would keep the FDA busy until the middle of 2002.
In December, two Wall Street analysts joined the ranks of those believing NAT was delayed, lowering 2002 earnings estimates for Chiron as a result.
Despite missing its self-imposed deadline for NAT approval, Chiron has yet to issue a statement as to what went wrong or to say whether it has a new timetable for approval. Chiron executives would not return calls seeking comment.The NAT blood-testing system, also known by the brand name Procleix, is designed to detect the presence of antigens such as HIV and hepatitis C in donated blood much earlier than current tests. NAT is Chiron's biggest potential growth driver, especially after the failure in November of its experimental sepsis drug. So, a long delay in the blood test's approval could force Chiron to reduce revenue and earnings estimates for the year. Wall Street's view of Chiron's 2002 earnings outlook is already weakening, with consensus estimates dropping a penny to $1.15 per share, according to Thomson Financial/First Call. Chiron closed out 2001 at $43.84 per share, a 1.5% drop for the year. Chiron shares closed Friday at $44.72.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV